Reditus partnering with ATA to combat antibiotic resistance among patients

Alexa Eichelberger, Reditus research associate, doing a DNA specimen transfer, which is part of the urine PCR (polymerase chain reaction) assay. 

Reditus Laboratories is partnering with Advanced Therapeutic Assist to combat antibiotic-resistant bacteria one patient at a time.

Many Reditus clients (health care providers including urologists and wound care specialists) have been asking for pharmaceutical treatment recommendations to be included in lab results that Reditus provides to the clinicians, said Reditus medical director Dr. Lorine (Lori) LaGatta. “By offering treatment recommendations based on lab results and taking patient clinical information into account, we are able to personalize the findings and elevate the product we can offer to our clients,” LaGatta said.

Reditus is announcing that it will be sending all urine and wound PCR (polymerase chain reaction) reports to Advanced Therapeutic Assist (ATA) to determine the best antibiotic to treat a patient’s urinary tract or wound infection. Therapeutic guidance paired with superior molecular diagnostic tools will optimize patient outcomes, reduce patient hospital admissions and significantly improve appropriate antibiotic treatments.

Antibiotic or antimicrobial resistance is growing worldwide, endangering the efficacy of antibiotics. The crisis has been attributed to misuse and overuse of antibiotics. As a result, the U.S. Centers for Disease Control and Prevention (CDC) and other organizations have been recommending improving microbial identification and optimizing therapeutic regimens.

“These findings highlight the need for quick and accurate pathogen identification, as well as the clinical relevance of the genetic resistant markers detected,” said ATA founder and CEO, Dr. Robin Prince. “ATA has designed protocols and clinical recommendations with providers in mind to facilitate utilization of information to provide the best antibiotic med class choice customized and personalized to each patient.”

“At Reditus Laboratories, we understand the importance of antibiotic stewardship and the importance of personalized pharmacotherapy,” LaGatta said.

ATA is an Arkansas-based health care consulting service that provides expert medication guidance to treating physicians. ATA specializes in resistant gene therapy. The service has completed more than 400,000 reports since its founding in 2018, said Prince, a practicing clinical pharmacist.

When ATA gets patient PCR lab results from a provider or a lab such as Reditus, the service, which includes 25 trained clinical pharmacists, interprets those results using a 12-step assessment that considers several factors, including patient allergies, age, gender, care setting and area of infection. The pharmacists read each report and produce a customized therapeutic guidance based on all relevant pathogens and corresponding relevant resistant genes detected along with any clinical notes concerning that specific patient. ATA’s comprehensive report includes a medication recommendation, dosage, duration, with special drug considerations all individualized for that specific patient.

Urine PCR is used for rapid detection of urinary tract pathogens and antibiotic-resistant genes, said Dr. Mike Sgambelluri, Reditus research scientist. “In one urine specimen, we test for 23 pathogens and 40 antibiotic-resistance genes simultaneously,” he said.

Wound PCR is used for rapid detection of bacterial and fungal pathogens commonly associated with wound infections, as well as antibiotic-resistance genes, Sgambelluri said. In one wound specimen, Reditus tests for 35 pathogens and 40 antibiotic-resistance genes simultaneously, he said.

The presence and quantity of pathogens and genes are tested to give physicians an idea of disease severity to determine the best treatment options. “We can get results to physicians within 24 hours of receiving a specimen,” Sgambelluri said.

ATA has developed a proprietary formula to predict antibiotic classes most likely to fail, therefore providing a report back to the provider with all the therapeutic med classes most likely to succeed.

Reditus will take that information and make it part of the urine and wound PCR test results that are sent to doctors’ offices to assist physicians in developing treatment plans for patients.

“Before, our reports would list the pathogens and resistance genes,” Sgambelluri said. “Now, before the results go to the physician, they first go to the pharmacist who interprets the results and makes treatment recommendations. So, not only will the physicians get the results faster but they will have the benefit of the pharmacist’s input.” For the patients, the benefit is a quicker, targeted treatment plan.

“Clinical pharmacists have been rounding with providers for years in the hospital setting,” Prince said. “Our community providers need to have access to the same level of team support. That’s what this is about. PCR with therapeutic guidance reviewed by real pharmacists not algorithms will give providers tools in their toolbox along with a telephone number to request additional guidance when peer-to-peer discussion is needed.”

Health care providers interested in learning more may contact Bryan Zowin, Reditus director of business development, at 309-340-3731, or Colton Moore, Reditus national key accounts consultant, at 309-533-0467.

“I am thrilled,” Prince said of partnering with Reditus. “I want to spread antibiotic stewardship in this format to everyone, improving health outcomes one patient at a time.”